DEA Reschedules Marijuana Contradictorily in 24 Hours

The DEA proposed rescheduling marijuana, withdrew that proposal within 24 hours, yet simultaneously rescheduled FDA-approved marijuana products to Schedule III. The contradiction creates confusion about federal marijuana policy and suggests internal conflict between scientific recommendations and enforcement priorities.

DEA Proposes Rescheduling Marijuana from Schedule I
The Drug Enforcement Administration has issued a proposed rule to reschedule marijuana from Schedule I to a lower schedule under the Controlled Substances Act. This unpublished Public Inspection document is scheduled for official publication on 04/28/2026. If finalized, this change would represent a significant reduction in regulatory restrictions on marijuana, affecting cannabis manufacturers, pharmaceutical companies, and other entities in the cannabis supply chain.

DEA Withdraws Marijuana Rescheduling Proposal
The Drug Enforcement Administration (DEA) has withdrawn its proposed rule to reschedule marijuana under the Controlled Substances Act. Marijuana remains classified as a Schedule I controlled substance, maintaining the most restrictive federal designation. There is no new compliance obligation imposed and no change to the current legal status of marijuana.

DEA Reschedules FDA-Approved Marijuana to Schedule III
The DEA has published a direct final rule rescheduling FDA-approved products containing marijuana from Schedule I to Schedule III of the Controlled Substances Act, with a corresponding change to permit requirements. The rule is scheduled for official publication on April 28, 2026, and represents a significant regulatory shift in how certain marijuana-derived pharmaceutical products are classified under federal law. This change will affect manufacturers, healthcare providers, and patients who handle or use these specific FDA-approved controlled substance products.